Trinity Delta Lighthouse: Oxford BioDynamics
Trinity Delta view: EpiSwitch CiRT addresses a clear need in helping guide ICI therapy, accurately differentiating between non-responders and responders, thus avoiding unnecessary side-effects and costs. The further clinical validation provided by PROWES data and the expectation that Oxford BioDynamics will apply for clinical guideline inclusion during 2025 should drive wider CiRT adoption by oncologists, growing test revenues, and making CiRT more attractive to potential partners. OBD’s near-term focus remains on securing one or more partnerships, collaborations and licensing deals to maximise the revenue potential of its portfolio of innovative and clinically robust tests. Longer-term sustainable test volume growth will require substantial ongoing commercial investment, and thus third-party partners or further funds are needed to deliver on the sizeable potential market opportunities for CiRT, PSE, and the EpiSwitch test portfolio. Commercial discussions are ongoing with multiple diagnostic/pharmaceutical companies, with a recent Google Cloud collaboration designed to make the OBD EpiSwitch platform more accessible to pharma and biotech companies and create future commercialisation opportunities.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.